TissueBlue
TissueBlue Uses, Dosage, Side Effects, Food Interaction and all others data.
Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures. This membrane is thin and translucent, making it difficult to identify during eye surgeries that require high levels of visual accuracy. TissueBlue, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.
Brilliant Blue G aids in ophthalmologic surgery by rendering it easier to identify the internal limiting membrane (ILM) for surgical removal.
| Trade Name | TissueBlue |
| Generic | Brilliant blue G |
| Brilliant blue G Other Names | Acid Blue 90, Brilliant blue G, C.I. Acid Blue 90, Coomassie Brilliant Blue G |
| Type | Ophthalmic |
| Formula | C47H48N3NaO7S2 |
| Weight | Average: 854.02 Monoisotopic: 853.28313753 |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
TissueBlue is a disclosing agent used in ophthalmological surgery to stain the internal limiting membrane (ILM).
This drug is indicated for selectively staining the internal limiting membrane (ILM).
How TissueBlue works
The internal limiting membrane (ILM) is a thin and translucent structure that demarcates the transition from the retina from the vitreous body of the eye. It acts as a scaffold on which excessive tissue can grow, which results in visual distortion when it is projected onto the neighbouring retina. This causes visual loss and/or distortion.
An epiretinal membrane (also known as ERM) is a fibrous type of tissue that can be found on the inner surface of the retina and occurs idiopathically, and in some cases, retinal detachment and inflammation. It is often found on the surface of the internal limiting membrane (ILM), causing visual loss and distortion. The above condition as well as the associated macular pucker or traction maculopathy can affect the ILM, contributing to visual complications. The removal of the ILM with or without vitrectomy is often a simple solution to these conditions.
Brilliant Blue G specifically stains the internal limiting membrane (ILM) in the eye without staining the epiretinal membrane or the retina, allowing for easier surgical removal. The mechanism of its specific staining that is limited to the ILM is currently not fully understood.
Toxicity
The intraperitoneal TDLO in rats is 100 mg/kg. No overdose information is available at this time. When compared to other ophthalmological dyes, brilliant blue G appears to have a comparable safety profile. Ensure to remove the dye immediately after staining.
Food Interaction
No interactions found.Volume of Distribution
This drug is administered via intravitreal injection and likely distributes only to parts of the eye.
Elimination Route
Due to the fact that this drug is administered by intravitreal injection and subsequently removed after staining, it is not expected to be significantly absorbed systemically.
Elimination Route
This dye is removed in a clinical setting after the surgical procedure in which it was used.
Innovators Monograph
You find simplified version here TissueBlue
